ESTRO 2025 - Abstract Book

S1711

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

Results:

A total of 29 patients were analyzed. Of the 28 patients who underwent surgery after neoadjuvant treatment, 26 patients (92.8%) underwent radical resection. pCR was achieved in 8 patients (27.5%), and 10 patients (34.5%) showed tumour regression of more than 50%. At a median follow-up of 29.3 months, disease progression was observed in 9 patients. Kaplan-Meier estimates showed a median disease-free survival (DFS) of 48.6 months. The 3 year overall survival (OS) rate was 80.7%, the 3-year DFS rate was 61% and the 3-year local progression-free survival (LPFS) rate was 86%. Grade 3 toxicity was observed in 3 patients (9.3%). During follow-up, wound complications occurred in 8 cases (27.5%) and mild limb dysfunction in 2 cases (6.9%). Conclusion: The combination of RT and HT showed promising oncological results, with a significant proportion of patients achieving a complete pathological response or substantial tumour regression. These results suggest that the addition of HT in combination with RT may improve local control and offer a potential therapeutic advantage.

Keywords: hyperthermia neoadjuvant radiochemotherapy